Latest news with #WesleyMayer
Business Wire
08-07-2025
- Health
- Business Wire
Avvio Medical's Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in
SAN FRANCISCO--(BUSINESS WIRE)-- Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Study highlights include: The AEROLITH study demonstrated that in the ureteral stone subgroup, a key clinical population, efficacy was comparable between URS-LL with microbubbles and URS-LL alone. However, the use of microbubbles demonstrated a significant safety advantage, including a 42% relative reduction in adverse events. 'This study demonstrates that conventional URS-LL, which currently is the most common surgical procedure to treat stones, yields disappointing results. More than 50% of patients will still have stones after the procedure, with residual fragments large enough to have a high chance for future problems,' stated Wesley Mayer, MD, lead author of the study. 'It is also poorly tolerated, with > 40% of patients reporting adverse events. AEROLITH showed that patients undergoing URS-LL augmented with microbubbles had significantly fewer adverse events, suggesting improved safety and tolerability compared to conventional laser lithotripsy.' These clinical findings further strengthen the growing body of evidence supporting Avvio's proprietary technology. Avvio Medical is also currently evaluating, in a pivotal multi-center clinical trial, the safety and effectiveness of Acoustic Enhancer Microbubbles delivered with its breakthrough Enhanced Lithotripsy System (ELS) utilizing low-intensity therapeutic ultrasound. For more information, visit About the Enhanced Lithotripsy System (ELS) The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy, enabling kidney stone treatments outside the traditional operating room and into more accessible outpatient settings like ambulatory surgery centers (ASCs), office-based labs (OBLs), and cystoscopy suites. The system delivers a single, minimally invasive therapy without the need for general anesthesia, fluoroscopy, intra-operative imaging, or costly capital equipment. By reducing procedural complexity and resource requirements, ELS supports wider patient access, improves care delivery efficiency, and offers meaningful clinical, economic, and health equity benefits. About Avvio Medical Avvio Medical is a privately held medical technology company based in San Francisco committed to expanding access to safer, more effective urinary stone treatments. By developing minimally invasive solutions that lower costs, reduce reliance on hospital-based care, and remove barriers like general anesthesia and advanced imaging, Avvio aims to improve patient outcomes, drive health system efficiencies, and close gaps in care access across diverse healthcare settings.
Yahoo
25-04-2025
- Health
- Yahoo
Avvio Medical to Present Clinical Trial Results at the 2025 American Urological Association Annual Meeting
Moderated Interactive Poster Session to Feature AEROLITH RCT Data on Acoustic Enhancer Microbubble Cavitation with Ureteroscopic Laser Lithotripsy SAN FRANCISCO, April 25, 2025--(BUSINESS WIRE)--Avvio Medical Inc. (formerly Applaud Medical, Inc.) today announced that results from its AEROLITH randomized clinical trial will be presented at the upcoming 2025 American Urological Association (AUA) Annual Meeting, taking place April 26-29 in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Moderated Interactive Poster PresentationPresenter: Wesley Mayer, MDTitle: A Prospective, Multi-Center, Randomized, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Ureteroscopic Laser Lithotripsy With and Without Acoustic Enhancer Microbubble Cavitation for the Treatment of UrolithiasisSession: IP08-22Date/Time: April 26, 3:30–5:30 PMLocation: Room Marco Polo 701 This clinical presentation adds to the growing body of evidence supporting Avvio's proprietary technology. Avvio Medical is also looking to initiate its forthcoming pivotal clinical trial evaluating the safety and effectiveness of Acoustic Enhancer Microbubbles delivered with its breakthrough Enhanced Lithotripsy System (ELS). "There is a clear need for improved and novel strategies in stone management," said Paul Molloy, President and Chief Executive Officer of Avvio Medical. "We are thrilled to advance our clinical research with our patented microbubbles and the Enhanced Lithotripsy System—a revolutionary approach to treating urinary stones." For more information, go to or visit Suite 115 at AUA and schedule a demo of the technology. About the Enhanced Lithotripsy System (ELS) The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers. About Avvio Medical Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company's system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals. View source version on Contacts Media Contact: Paul MolloyChief Executive OfficerAvvio Medical, Tel: (415) 887-2037 Sign in to access your portfolio
Associated Press
25-04-2025
- Health
- Associated Press
Avvio Medical to Present Clinical Trial Results at the 2025 American Urological Association Annual Meeting
SAN FRANCISCO--(BUSINESS WIRE)--Apr 25, 2025-- Avvio Medical Inc. (formerly Applaud Medical, Inc.) today announced that results from its AEROLITH randomized clinical trial will be presented at the upcoming 2025 American Urological Association (AUA) Annual Meeting, taking place April 26-29 in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Moderated Interactive Poster Presentation Presenter: Wesley Mayer, MD Date/Time: April 26, 3:30–5:30 PM Location: Room Marco Polo 701 This clinical presentation adds to the growing body of evidence supporting Avvio's proprietary technology. Avvio Medical is also looking to initiate its forthcoming pivotal clinical trial evaluating the safety and effectiveness of Acoustic Enhancer Microbubbles delivered with its breakthrough Enhanced Lithotripsy System (ELS). 'There is a clear need for improved and novel strategies in stone management,' said Paul Molloy, President and Chief Executive Officer of Avvio Medical. 'We are thrilled to advance our clinical research with our patented microbubbles and the Enhanced Lithotripsy System—a revolutionary approach to treating urinary stones.' For more information, go to or visit Suite 115 at AUA and schedule a demo of the technology. About the Enhanced Lithotripsy System (ELS) The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers. About Avvio Medical Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company's system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals. View source version on CONTACT: Media Contact: Paul Molloy Chief Executive Officer Avvio Medical, Inc. Email:[email protected] Tel: (415) 887-2037 KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH SURGERY CLINICAL TRIALS SOURCE: Avvio Medical Inc. Copyright Business Wire 2025. PUB: 04/25/2025 12:45 PM/DISC: 04/25/2025 12:46 PM
Business Wire
25-04-2025
- Health
- Business Wire
Avvio Medical to Present Clinical Trial Results at the 2025 American Urological Association Annual Meeting
SAN FRANCISCO--(BUSINESS WIRE)-- Avvio Medical Inc. (formerly Applaud Medical, Inc.) today announced that results from its AEROLITH randomized clinical trial will be presented at the upcoming 2025 American Urological Association (AUA) Annual Meeting, taking place April 26-29 in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Moderated Interactive Poster Presentation Presenter: Wesley Mayer, MD Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Ureteroscopic Laser Lithotripsy With and Without Acoustic Enhancer Microbubble Cavitation for the Treatment of Urolithiasis Session: IP08-22 Date/Time: April 26, 3:30–5:30 PM Location: Room Marco Polo 701 This clinical presentation adds to the growing body of evidence supporting Avvio's proprietary technology. Avvio Medical is also looking to initiate its forthcoming pivotal clinical trial evaluating the safety and effectiveness of Acoustic Enhancer Microbubbles delivered with its breakthrough Enhanced Lithotripsy System (ELS). 'There is a clear need for improved and novel strategies in stone management,' said Paul Molloy, President and Chief Executive Officer of Avvio Medical. 'We are thrilled to advance our clinical research with our patented microbubbles and the Enhanced Lithotripsy System—a revolutionary approach to treating urinary stones.' For more information, go to or visit Suite 115 at AUA and schedule a demo of the technology. About the Enhanced Lithotripsy System (ELS) The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers. About Avvio Medical Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company's system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals.
